Sara Coca Membribes, GU Clinical Research Fellow at Barts Health NHS Trust, shared on X:
“New biomarker analysis from TALAPRO-2.
Baseline ctDNA and early dynamics correlated with rPFS, adding prognostic value beyond PSA in some patients Integrating ctDNA, circulating tumour cells and PSA warrants further exploration.”
Title: Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
Authors: Steven M Yip, A Douglas Laird, Neeraj Agarwal, Stefanie Zschäbitz, Karim Fizazi, Nobuaki Matsubara, Jae Young Joung, Lawrence I Karsh, Joan Carles, André P Fay, Josep M Piulats, Peter C C Fong, Glenn Liu, Lee A Albacker, Lincoln W Pasquina, Jijumon Chelliserry, Cynthia G Healy, Xun Lin, Matko Kalac, Arun A Azad
You can also read:
